扎鲁替尼

扎鲁替尼（CAS 1691249-45-2）的独立参考数据，整理自公开化学数据库。

各数据库的登记标识

计算分子描述符

在册的记载用途

Zanubrutinib is indicated for the treatment of: - Mantle cell lymphoma (MCL) in adults who have received at least one prior therapy. - Waldenström’s macroglobulinemia in adults. - Relapsed or refractory marginal zone lymphoma (MZL) in adults who have received at least one anti-CD20-based regimen. - Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in adults. - Refractory or relapsed follicular lymphoma, in combination with [obinutuzumab], in adults who have received at least two prior systemicZanubrutinib is an oral inhibitor of Bruton’s tyrosine kinase that is used in the therapy of refractory mantle cell lymphoma. Zanubrutinib has been associated with a low rate of serum enzyme elevations during therapy, but has not been linked to cases of clinically apparent acute liver injury although it may pose a risk for reactivation of hepatitis B in susceptible patients.

同义词与商品名

Zanubrutinib; 1691249-45-2; Brukinsa; BGB-3111; AG9MHG098Z; DTXSID701026208; zanubrutinibum; BTK-InhB; RefChem:57294; DTXCID701510461; Zanubrutinib [INN]; Zanubrutinib [USAN]; BGB3111; UNII-AG9MHG098Z; 1691249-45-2 (S-isomer); Zanubrutinib (BGB-3111)

GHS 危害分类

Reported hazard statements	H360 (100%)

H360 (100%): May damage fertility or the unborn child [Danger Reproductive toxicity]

H360D (100%): May damage the unborn child [Danger Reproductive toxicity]

公开数据库对它的描述

Zanubrutinib · CAS 1691249-45-2 · C27H29N5O3. UNII AG9MHG098Z.

物理形态与操作说明

数据来源：PubChem / Wikidata；与随货 COA 不一致时以 COA 为准。